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The finding that certain neoplasms have a  requirement  for L-asparagine, an 
amino acid commonly regarded as nutritionally nonessential, provides the basis 
of a  unique  form of cancer therapy. 
In 1953, Kidd (1, 2) observed that certain transplanted murine leukemias were sup- 
pressed by treatment with guinea pig serum,  The work of Broome  (3-5)  established 
that the active factor in guinea pig serum is L-asparaginase.  x His main evidence was as 
follows: First, the chemical properties of the leukemia-inhibitory factor did not differ 
from those of L-asparaginase of guinea pig serum, and in various fractionation proce- 
dures the leukemia-inhibitory activity was always associated with  T-asparaginase ac- 
tivity. Secondly, 6C3HED,  the leukemia used in his studies, was found to require L- 
asparagine for optimal growth in culture, and cells cultured continuously in the pres- 
ence of I.-asparagine retained their sensitivity to suppression by guinea pig sera in vivo; 
on the other hand, sublines of 6C3HED that hadlost their requirement for l.-asparagine 
as a result of culture in vitro in media lacking l.-asparagine were no longer suppressed 
by guinea pig serum in vivo. Finally, sublines of 6C3HED that had been made resistant 
to guinea pig serum by exposure to subeffectlve doses in vivo did not require L-aspara- 
gine for immediate growth in culture. 
Later studies provide further evidence that the leukemia-inhibitory factor in guinea 
pig serum is l.-asparaginase. First, the sera of animals closely related to the guinea pig 
(three  genera  of  the  same  supeffAmily, Ca~oidea) have  both  L-asparaginase  and 
leukemia-inhibitory activities  (6, 7); in contrast,  no serum lacking L-asparaginase is 
effective against leukemias  (1, 5-8).  Secondly,  l.-asparaginase prepared  from a  bac- 
terial source,  F.scherich~ coU~ suppresses 6C3HED  and the DBA/2 leukemia P1534 
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1 L-asparagine  amidohydrolase  (EC 3.5.1-1) 
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(9). Subsequently, two enzymes, caUed EC-1 and EC-2 were separated  ~rom E. coli; 
they differ in their chemical properties and only one of them  (EC-2)  has leukemia- 
inhibitory activity (10). 
Susceptibility to suppression by guinea pig serum is now known to be a  common 
property of certain classes of leukemia in the mouse (11).  Susceptibility is not con- 
fined to murine leukemias; the Murphy-Sturm lymphosarcoma of the rat (1)  and two 
other rat  tumors, Walker carcinosarcoma 256  (12)  and ACMCA2 sarcoma  (13), are 
reported to be susceptible. 
This communication is concerned with a  comparison between L-asparaginase 
from guinea pig serum and L-asparaginase from E. coli in the treatment of the 
transplanted radiation-induced leukemia EARAD1.  In addition,  we have ex- 
tended our previous survey of murine leukemias (11) to a total of 109 leukemias 
that have now been tested for susceptibility to guinea pig serum. 
Materials and Methods 
Leukemias.--AU  the leukemias used in this study were induced, or arose spontaneously, in 
mice of our colonies. Methods of induction  by X-radiation, chemical carcinogens, and leukemia 
viruses (Gross, Friend, Moloney, Ranscher) are described in previous publications from this 
laboratory  (see  reference  14). The leukemia used  in most  of  the  studies reported  here, 
EARAD1, was induced by X-radiation in a (C57BL/6 X  A)FI hybrid female of our colony in 
1961 and has been maintained exclusively by passage in isogenic  (C57BL/6 X  A)F, 9  mice. 
At the time of these experiments, it was in its 27th-148th transplant generations. 
Guinea Pig Serum (GPS).--Hartley gtfinca pigs weighing more than 350 g were bled from 
the heart under ether anesthesia, the sera were pooled after separation and centrifugation, and 
the pools were stored at -70°C. The L-asparaginase  activity of these pooh ranged from 115- 
140 units/ml. 
Tests of Leukemias of Various Types for their Sensitivity to GPS.--Ym the survey summarized 
in Table HI leukemias were tested for sensitivity to GPS by inoculating a counted number of 
viable cells (usually 1 X  109 subcutaneously  into 10 isogenic mice, five of which received I mi 
of GPS intravenously  and 1 ml intraperitoneally within an hour of the inoculation of the leu- 
kemia cells, the other five serving as controls. Sensitivity to GPS was indicated by either com- 
plete protection or marked prolongation of survival time. 
Enzyme Assays.--The L-asparaginase  assays were carried out as described elsewhere  (10). 
One unit of activity is that quantity of enzyme which releases  1 zmole of ammoni~ from L- 
asparagine per hour at the maximum rate. The clearance of GPS and E. coli (EC-1 and EC-2) 
L-asparaginases was determined by injecting  the stated amount of GPS or enzyme preparation 
intravenously  or intraperitoneally  as indicated in Fig. 5. Blood was obtained by cardiac punc- 
ture from two mice for each time interval, and the pooled serum was stored frozen until as- 
sayed for x-asparaginase. 
Preparation of the L-asparaginases EC-1 and EC-g from E. coli B ¢dls.--The preparation of 
EC-1 and EC-2 is described  fully in a separate report dealing with the chemistry of the two 
enzymes (10). In summary, a ceU-frec extract of E. coli B cells is treated with M-.nCh to pre- 
cipitate nucleic acids and the two enzymes are partially separated  by fractional precipita- 
tion with ammonium sulphate; further separation of EC-1 and EC-2 is effected by chrom- 
atography on hydroxylapatite and DEAE-ceUulose columns. With the exception of the EC-1 
preparation used in studying clearance rates (Fig. 5), all the experiments reported here were 
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RESULTS 
Sensitivity of Leukemia EARAD1  to GPS.--Table  I  shows the effect of GPS 
administered in various doses and by various routes on the outgrowth of 1 X 
10  6 cells of the  GPS-sensitive leukemia EARAD1  inoculated  subcutaneously 
approximately 1 hr before the administration of GPS. The subcutaneous route 
(distant from the site of leukemia inoculation),  the intraperitoneal route, and 
the intravenous route of injection were almost equally effective. This pool of 
TABLE  I 
Influence of Dosage and Route of Administration 
on the Inhibitory Action of Guinea Pig Serum 
Leukemia: EARAD1 (C57BL/6 X A) FI* 
Groups 
Controls 
I 
II 
III 
IV 
Treatment 
Volume of GPS  Route 
.d 
0.1  s.c. 
i.p. 
i.V. 
0.25  s.c. 
i.p. 
i.V. 
0.5  s.c. 
i.p. 
i,v. 
1.0  s.c. 
i.p. 
i.V. 
No. mice without 
[  leukemia/No. 
mice tested 
0/8  21, 
0/4  25, 
0/4  24, 
0/4  22, 
o/4 
1/4 
t/4 
4/4 
4/4 
4/4 
3/3 
3/3 
3/3 
Survival time of 
leukemic mice 
days 
22, 24, 24, 24, 24, 24, 24 
25, 27, 28 
25, 30, 32 
25, 27, 28 
27, 28, 28, 29 
30, 32, 27 
30, 32, 33 
All survived 
All survived 
* GPS injected approximately 1 hr after inoculation of leukemia cells. 
GPS produced complete suppression of EARAD1 at a dose of 0.5 ml; a dose of 
0.1 ml caused slight prolongation of survival but no absolute protection. 
Table II indicates that the effectiveness of GPS is related to the number of 
leukemia cells inoculated. With 1 ml GPS injected intravenously at the time of 
inoculation of leukemia cells there was complete protection of all mice inocu- 
lated with 1 X  10  e EARAD1 cells and of some mice inoculated with 3  X  106 
cells.  There were no survivors in groups receiving 9  X  l0 s or more cells. In- 
creased survival time was observed in all mice given GPS,  regardless of the 
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Survey of a Series of Murine Leukemias for their Sensitivity  to GPS.--Table 
III is a  summary of our experience up to the present time regarding the in- 
cidence of sensitivity to GPS among leukemias of several types. The 109 leu- 
kemias listed in Table III were for the most part in very early transplant gener- 
ations and include the  18 leukemias  reported previously (11).  Sensitivity is 
evidently a common characteristic of certain classes of leukemia; in particular, 
of leukemias induced by X-radiation  (21/48) and of leukemias arising spon- 
taneously in strains that have a low incidence of leukemia, 5/14 in the C57BL/ 
6,  A, BALB/c, I  and DBA/2 strains.  Of leukemias arising spontaneously or 
induced in strains that have a high incidence of leukemia, sensitivity to GPS is 
uncommon, 1/12 in the AKR and C58 strains. No instance of sensitivity was 
TABLE H 
Influence of the Number of Leukemia Cells Inoculated on the Inkib4tory Action 
of Guinea Pig Serum 
Leukemia: EARAD1 (C57BL/6 X A) FI* 
No. leukemi~ cells 
inoculated sub- 
cutaneously (X10  6) 
1 
3 
9 
12 
24 
48 
* 1 ml  GPS  ir 
No. mice without leukemia/No, mice tested 
Controls  (no  GPS) 
0/4 
0/5 
0/4 
0/4 
o/4 
o/3 
Treated with GPS 
4/4 
2/5 
0/4 
O/4 
0/4 
O/3 
ected intravenously  approximately 
Survival time of leukemic mice, days 
Controls (no GPS) 
24, 24, 24, 24 
20, 20, 20, 24, 24 
19, 19, 19, 20 
19, 19, 19, 20 
19, 19, 19, 20 
17, 20, 2O 
Treated with GPS 
All survived 
34, 45, 52 
24, 28, 30, 45 
28, 28, 34, 58 
28, 28, 28, 28 
24, 28, 30, 45 
hr after inoculation of leukemia  cells. 
found  among  16  leukemias  induced  by  the  Gross,  Friend,  Moloney,  and 
Rauscher leukemia viruses. 
Effectiveness  of GPS in Comparison with a Number of Commonly Used Chemo- 
therapeutic  Agents.--Three  leukemia.s,  two  of  them  GPS-sensitive,  and  one 
GPS-resistant, were selected for the experiments shown in Table IV. With the 
exception of their response to GPS all three leukemias showed approximately 
similar sensitivities to each particular chemotherapeutic agent. In other words, 
the two GPS-sensitive leukemias did not differ from the GPS-resistant leuke- 
mia in their responses to this range of cytotoxic drugs. A striking feature of such 
comparative studies, in addition to the remarkable effectiveness of GPS in af- 
fording absolute protection, is that GPS-treated mice show no weight loss  or 
signs of toxicity. (Survival times of mice with EARAD1 were not affected by 
the administration of 2.5 g/kg D-asparagine or L-asparagine daily for 10 days.) 
Comparative Effectiveness  of E.  coll z-asparaginase and GPS, under  Various 
Conditions of Testing, in the Treatment of Leukemia EARADI.-- TABLE HI 
Susceptibility to Suppression by Guinea Pig Serum of 109 Mouse Leukemia,  s 
Strain of origin 
C57BL/6 
(C57BL/6 X A)F1 
A 
BALB/c 
C3H/An 
(BALB/c X C3H/An)F1 
C58 
I 
AKR 
DBA/2 
(C3H/An ×  I)F1 
C3HUBi 
Total ................. 
Mode of induction 
Spontaneous X-Radiation  Urethan  DMBA  Virus 
Sens.  Res.  Sept.  Re$. 
1  2 
1  2 
2 
4 
2  3 
1 
1 
5  14 
Sens.  Res. 
11  12 
6  8 
2  3 
1  2 
1 
1  1 
21  27 
Sens.  Res. 
1  6 
1 
1 
1 
1  1 
2 
2  12 
Sen&  Res. 
2 
1 
4 
5 
12 
3M 3R 
1M 
3G 3M 
1M 
IF 
1G 
16 
Abbreviations:  M, Moloney virus; G, Gross (Passage A) virus; F, Friend virus (trans- 
planted solid tumor variant); R, Ranscher virus; DMBA, 9,10-dimethyl-1,2-benzanthracene; 
Sens., sensitive to suppression by GPS; and Res., resistant to suppression by GPS. 
TABLE IV 
Comparative Sensitivities of T~oo GPS-Sensitiv¢ Leukonias and One GPS-Re.rislant 
Leukemia to Various Chonotherapeut~ Agents 
EARADt  RADAI$  ASLI~  Total daily  dose*  (radiation-  (radiation-  induced)  induced) (spontaneous) 
Guinea pig serum 
6-Mercaptopurine 
Prednisone 
Guanylhydrazone 
NSC 60339 II 
Methotrexate 
Azaserine 
5-Finorouracil 
Cytoxan 
Vineristine 
Mitomycin C 
3 ml day 0 (i.p. and s.c.) 
2 ml day I  (s.c.) 
30 mg/kg 
30 mg/kg 
50 mg/kg 
16 mg/kg 
1 mg/kg 
10 mg/kg 
13 mg/kg 
200 mg/kg 
(one dose) 
0.2 mg/kg 
1 mg/kg 
Per cent i~rease in survival  tlra¢ (5 m&e per graup)§ 
5/5 survived  -1  +93 (1 mouse) 
4/5 survived 
+12  --12 
+4  +11 
+6  +20 
+4  +1 
+36  +22 
+95  +81 
+19  +11 
+41  +39 
+3 
+5 
+2O 
+4 
+36 
+111 
+41 
+80 (4 mice) 
1/5 survived 
+7 
+12 
+3 
+16 
--34 
--21 
* With the exception of GPS, cytoxan, and prednisone, all compounds were administered 
in 10 daily doses, starting 4 hr after subcutaneous inoculation of 10  e leukemia cells. Predaisone 
was injected for 10 days twice daily subcutaneously, except for day 0 when the total daily 
dose was given in one intraperitoneal injection. Cytoxan was given on day 0 only. With the 
exceptions noted, all injections were intraperitoneal. 
~; Origins of these leukemias of the A strain are given in reference 15. 
§ Based on survival times of 20 control mice treated with the diluent (saline or earboxy- 
methylceUulose),  or not injected. 
]]  NSC 50339 ffi 2-chloro-4~,4n-bis(2-imidazolin-2-yl)terephtha~anilide. 
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Treatment at the time of inoculation  of leukemia cells: Groups of mice were 
inoculated subcutaneously with 1 X  ] 06 EARAD 1 cells and were treated within 
1 hour with E. coli L-asparaginase EC-2 intraperitoneally in a dose of 50,  200, 
or 2000 units,  or with  GPS in dose of 50 or 200  units  L-asparaginase. Fig.  1 
shows the result of this experiment. During the first 12 days after inoculation 
GPS gave suppression at 200 units/mouse and partial suppression at 50 units. 
EC-2 was completely ineffective at 50 and 200 units; 2000 units EC-2 was less 
effective than 50 units  GPS L-asparaginase. The survival times of these mice 
are given in Table V  where it is seen that EC-2 gave no increase in survival 
time even in the highest dose of 2000 units.  GPS at 200 units gave prolonged 
survival of three mice and permanent protection of one mouse. 
Thus EC-2 administered at the time of inoculation of leukemia cells confers 
virtually no protection. 
f  50 units (4 mice)-~ 
EC-2 ~ 200 units (3 mice}-,\  ,  ,  / 
--  /  2000 units (4 mice)\\  ./~,,"  / 
Controls=  no treatmen 
412  (.5 mice)  t'" i  \.-  ,,/ 
1' //,/\  it/  GPS"  50 units 
,y  ,,m,ce)  \/ 
o  4 
*  o  '  i'2 
l  Days after Inoculation of Leukemia  EARAD1 
Single injection of 
GPS or EC-2 
FIO. t.  Comparative effectiveness  of GPS and E. coli EC-2 administered [ntraperitoneally 
within 1 hr after subcutaneous inoculation of leukemia EARAD1. 
Treatment commencing  7 days after inoculation  of leukemia cells: Fig. 2 shows 
the effect of a single injection of 50,  200,  or 2000 units of EC-2 or of a single 
injection of GPS containing 50 or 200 units,  administered 7 days after subcu- 
taneous inoculation of 3.5  X  106 EARAD1 cells. At this time the subcutaneous 
mass  is  approximately  1  cm  in  diameter  and  the  leukemia  is  generalized 
(demonstrated by transmitting the leukemia with cells taken from the spleens 
of animals  inoculated  subcutaneously  7  days previously). In contrast  to  the 
failure  of EC-2  to  protect  when  administered  at  the  time of  inoculation  of 
EARAD1,  EC-2 was highly effective in the treatment of these established  7- 
day transplants.  Guinea pig serum, on the contrary, is relatively less effective 
when administered after the leukemia is established. Suppression by EC-2 was 
most marked at 2000 units, with one permanent cure in the group of four mice 
(Table V). TABLE V 
Comparison of Guinea Pig Serum L-asparaginase wiZk R. coli L-asparagi,ase 
EC-2* in the Treatmen~ of Leukemia EARAD1 I~wculaZed Either (a)  on the 
Same Day, or (b) 7 Days Previously 
No. of  I  Source of  [  mice  L-asparaginase  Units  Day of death 
Total dose as one injecsion on day 0 
2O  None (controls) 
GPS 
E. coli 
GPS 
E. coti 
E. coli 
50 
50 
200 
200 
2000 
15  16  16  17 
20  21  25  25 
16  17  17  19 
25  40  47  >120 
16  17  20 
17  19  19  20 
Total dose as one injection on day 7 
19  None (controls) 
GPS 
E. coil 
GPS 
E. coli 
E. coli 
m 
5O 
5O 
200 
2O0 
2000 
16  16  16  16 
16  16  17  17 
17  18  18  19 
19  20  21  23 
19  21  22  22 
34  35  42  >120 
Ten dose,  s on days 7-11 
GPS 
E. coli 
200 
(20U X  10) 
200 
(2ou x  lO) 
20  20  21  22 
20  21  21  22 
* The same preparation of E. coli L-asparaginase and of GPS was used for the entire ex- 
perlment shown in this Table. 
GPS:  50 units(4 mice)  \....~.i  1j. 
y  ./° 
p,  16  -/  EC "  f  -"~"  f.,"  "Z;:  / 
/'/  50 units  ~.'d 
d-~Z':  (4 mice).  ./GPS.- 200 units 
12  ./..~....::)~  ....  .....  \/  ./'  (4 mce) 
CulltiUl~:  /  ." 
-  ~'~  no treatment  //  / 
\  '~;~,  j  ....  EC-2: 200units\  ~. 
;~'  4  ~'~\'~,  ///\  ,-~-  ~  ....  (4mice)j."'._ 
\\  /"   c-a 
o  ...........  mi2  ) 
I  I  I  I  I  I  I  I  I  I  I  I 
<  7  8  9  10  11  12  13  14  15  16  17  18 
Days  after Inoculation  of Leukemia  EARADI 
Single injection of  I  G  PS or EC-2  I 
FIG. 2.  Comparative effectiveness of GPS and E. coli EC-2 administered  intraperitoneally 
7 days after subcutaneous inoculation of leukemia EARAD1. 
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Fig.  3 shows the effect of divided doses of EC-2  or  GPS  administered on 
days 7-11  (the day of inoculation being regarded as day 0). Again EC-2, at a 
dose of 200 units (20 units X  10), was markedly more effective than GPS in 
suppressing the local tumor. 
16 ]--  .,.'"Controls:  no treatment 
=o  14 L  ..  ..........  (5 mice)  -"'-'- 
~-  12[  ..."  "'""  "  .......  G/PSi4\ mice) 
X.  ,  EC-2  (4 mice}  I."" 
tt  tt  tt  tf  tt  ...........  ~----~" 
OLlo injections of GPS or FC-2 
o~ 
,  ,  ]  ,  i  ,  I  i  I  ;  I  , 
7  11  13  15  17 
Days after Inoculation of Leukemia EARAD1 
FIo. 3.  Comparative effectiveness of GPS and E. coli EC-2 adm~n;-qtered intraperitonea]ly 
on  days 7-11  after subcutaneous inoculation of leukemia EARAD1.  (20  units  X  10:  total 
200 units).  ,ii  __..Leuk°m'cm'ce'rea' w'th""ne  Normal mice treated  with saline 
31  ......  Leukemic mice treated  with L-asparaginase  EC-2 
~29  Normal mice treated  with L-asparaginase EC-2 
=  ...........  .~..:..m..:-.  -=.' .  \  ..-- ......... 
23~-  "-  / 
ff  tf  ~t  tf  tt  ~" .... 
P 
m 
10 injections of  EC-2  or saline 
<  19  ,  I  ,  l  ,  l  ,  I  ,  I  ,  I  ,  I  ¢  l  ,  I  ,  I  = 
0  2  4  6  8  i0  12  14  16  18  20 
Days after Inoculation of Leukemia  EARADI 
FIG. 4.  Effect of 10 intraperitoneal injections of 200 units EC-2 (total 2000 units in 5 days) 
on the weights of normal mice and mice with 7-day transplants of leukemia EARAD1. 
Treatment of nonleukemic animals with EC-2 preparations of the type used 
in  these tests does  not  cause  loss  of  weight  or  obvious  toxicity,  although 
leukemic animals lose weight which they recover after treatment (Fig. 4). 
Permanent Cure of Mice with Established Leukemic  Transplants by Treatment 
~ith EC-2 Beginning on the  7tk Day after Inoculation  of Leukemia Cells.--A 
high proportion of mice with 7-day transplants of EARAD 1 can be permanently BOYSF.~ OLD~ CAMPBELL~ AND MASHBURN  25 
TABLE  VI 
Perraanerg Cure of Mice ~i~t; 7-Day Transplants of EARAD1 by 
E. ¢oli L-asparaginas¢ EC-2* 
Mouse No. 
41~ 
4123 
4084 
4089 
4093 
4017 
4125 
4133 
4073 
4131 
4091 
4085 
4098 
4O99 
4090 
4136 
4104 
4109 
4126 
4105 
4106 
4045 
4086 
4134 
4092 
4118 
4097 
4135 
4132 
Total units (.p.)  Notes 
I000 
(lOO  x 
2OOO 
(2OO  X  I0) 
40OO 
(40o  x  IO) 
None (controls given 
buffer alone) 
Died on  Survivors  day 
23  0/6 
23 
25 
25 
27 
24 
31 
(37) 
17 
21 
16 
17 
19 
22 
20 
15 
18 
17 
17 
18 
5/6 
4/5 
0/12 
Rechallenged 6 months later with 
50,000 cells s.c.:  all died of leu- 
kemia. 
Rechallenged 6 months later with 
50,000 cells s.c.:  all died of leu- 
kemia. 
Sacrificed with recurrence on day 3~ 
(C57BL/6 X A)F1 ~ leukemia EARAD1 inoculated s.c. on day 0 into (C57BL/6 X A)FI 
mice (average weight, 20 g). Treatment started on day 7, at which time the subcutaneous 
mass measured 10 X 10 mm (average). 10 injections (two per day) on days 7-11. In all treated 
animals the s.c. mass was no longer visible or palpable on day 9. 
* Specific activity: 315 uuits/mg protein. 
Transplanted and identified as resistant variant by failure to respond to GPS. 
cured by treatment with 2000 or more units of EC-2. All survivors from the 
experiment shown in Table VI were observed for at least 6 months after treat- 
ment. As these 6-month survivors were fully susceptible to rechaUenge with 
minimal numbers of EARAD1 cells  (Table VI) it is clear that cure must be 26  SUPPRESSION  OF I~[URINE  LEUKEMIAS  BY L-ASPARAGINASE 
ascribed solely to the action of x-asparaginase  and not to any immune reaction 
accompanying therapy with L-asparaginase. 
Blood  Clearance  of GPS z,-asparaginase  and  E.  coli  z-asparaginase.--Two 
z-asparaginases,  EC-1  and EC-2,  have been isolated  from E.  coli  (10). They 
can be partially separated by (NH4)2SO4-fractionation and they differ in chro- 
matographic properties and in enzymatic activity in relation to pH. Only EC-2 
has leukemia-inhibitory activity. 
Fig. 5 shows clearance data for GPS L-asparaginase and for EC-1 and EC-2 
from E. coll. GPS L-asparaginase is cleared from the serum at a slow rate (half- 
life after equilibriation  approximately 26 hr for GPS injected intravenously). By 
~'~" 0.4"1~,,  ~ 
o  E 
.E'~ 0.3- 
~E 
~ ~  0"2~  4~(t93unlts/m°use]  -  i 
~-~  A~,iv.  (161 units/mouse,  i 
"~  ~  EC-2,  i.p.(]6] units/mouse) 
I1.-,..i1._  ~  I 
0  4  8  12  16  20  44 
]  Time (hours after injection) 
I EC-I, i9.(1~ units/mouse)  I 
FIO.  5.  Clearance of GPS L-asparaginase,  EC-I  L-asparaginase,  and EC-2  L-asparaghaase 
after intraperitoneal or intravenous inoculation. 
contrast, EC-2 is cleared rapidly, the rates for intraperitoneal and intravenous 
injection being similar except for the period of equilibration (half-life approxi- 
mately 150 rain). No rate of clearance from the blood  can be estimated for 
enzyme EC-1 because apparently very little of the enzyme left the peritoneal 
cavity, or alternatively the half-life of the enzyme in vivo is very short (Fig. 5). 
DISCUSSION 
As a preliminary to discussion of the findings  reported here we may consider 
the accumulated evidence that the inhibitory factor in GPS is L-asparaginase 
and that the inhibition of GPS-sensitive neoplastic cells  is a consequence of a 
specific  nutritional requirement for L-asparagine. 
I. Fractlonation  of GPS (3,  4, 16-20) shows  that  fractions  with inhibitory  activity 
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2.  Sera that  contain  L-asparaginase  will  suppress  GPS-sensitive leukemias; sera 
that do not contain L-asparaginase  do not suppress these leukemias (1, 6-8). 
3.  Four murine leukemias and one tumor of the rat that have been found to re- 
quire I,-asparagine for their growth in vitro, (6C3HED (3, 5), EARAD1 (17), L5178Y 
(reference  21  and  unpublished  observations),  P1798  (unpublished  observations), 
and Walker carcinosarcoma 256 (22)), are sensitive to suppression by GPS  in  vivo. 
Two other cell lines are known to require L-asparagine  in vitro, (Jensen rat sarcoma 
(23) and a hepatoma of the rat (24)), but these have not been tested for sensitivity to 
GPS in vivo. Conversely, many routine cell lines are known to have no requirement for 
L-asparagine  in vitro and are not sensitive t6 GPS in vivo. During a recent study in 
this laboratory 12 transplanted routine leukemias that were known to be insensitive to 
GPS in vivo were successfully grown in culture and none of these exhibited a require- 
ment for I~asparagine (B.  Stambuck, B. Williamson,  E. A. Boyse, and L. J. Old, in 
preparation). 
4.  Cells  that lose  their requirement for L-asparagine  in vitro are no longer  sup- 
pressed by GPS in vivo and leukemia cells that have been rendered insensitive  to GPS 
by suboptimal treatment in vivo no longer require L-asparagine  for growth in vitro; 
this has been shown for 6C3HED  (3, 5), and for EARAD1 and P1798  (unpublished 
observations). 
5.  As reported here and previously (9) L-asparaginase  from E. coli is as active as 
GPS against GPS-sensitive leukemias. The great phylogenetic disparity between these 
two sources makes it virtually certain that the inhibitory factor in GPS is I.aspara- 
ginase and not a protein with properties dosely related to ~-asparaginase; it suggests 
furthermore that the inhibitory action derives from its deamidating activity and not 
from other regions of the L-asparaginase  molecule. 
The finding that certain leukemias and other tumors have a  specific nutri- 
tional requirement for L-asparagine constitutes the only established instance of 
a  defined  biochemical  difference  between  neoplastic  cells  and  their  normal 
precursors. The suppression of such leukemias by L-asparaginase thus  consti- 
tutes the only specific therapy known at the present time for any form of cancer. 
The extraordinary effectiveness of L-asparaginase is particularly well illustrated 
when  seen  in  comparison  with  various  standard  chemotherapeutic  agents 
(Table IV). The virtually all-or-none response to L-asparaginase  (depending 
upon the susceptibility or resistance of particular leukemias) contrasts with the 
less discriminating and less effective responses to treatment by cytotoxic drugs 
and hormones, which are exerting differential effects upon neoplastic and nor- 
mal tissues. Clearly, the absence of toxicity of L-asparaginase, which makes it 
possible to treat with very high doses, derives from its specificity of action. 
The detection  of leukemia-inhibitory activity of L-asparaginases from dif- 
ferent sources is dependent upon the circumstances under which the enzymes 
are  assayed.  GPS L-asparaginase is most effective when  administered  at the 
same time as the leukemia cells,  under which condition E. coli L-asparaginase 
confers no protection. In the treatment of established tumors that have already 
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GPS  (on the basis of equivalent numbers of units administered). A  striking 
difference between the GPS and E. coli enzymes is the more rapid clearance of 
the latter (Fig. 5). The failure of EC-2 in the concurrent treatment of inoculated 
leukemia may be partly attributable to its rapid clearance, but this cannot be 
the only factor as it is effective in the treatment of established transplants. It is 
necessary to postulate that the requirement for L-asparagine is related to phases 
of the growth cycle of asparagine-dependent cells. Shortly after transplantation 
the cells  may be metabolically inactive and the demand for asparagine cor- 
respondingly reduced. Later, when the cells enter a phase of growth their re- 
quirement for asparagine is presumably increased and at this time they may be- 
come susceptible to asparagine-deprivation once more. This would account for 
the effectiveness of GPS in the treatment of newly inoculated leukemia cells 
because asparagine-deprivation in this case would persist beyond the lag-phase 
of the inoculated cells, whereas in the case of the rapidly cleared EC-2, serum 
and tissue asparagine may already have returned to levels adequate for growth 
of the leukemia cells. 
The inactivity of other L-asparaginases such as E. coli EC-1 (10)  and yeast 
L-asparaginase (25) can be explained on the basis of exceedingly rapid clearance 
or inactivation. Other contributory factors may include low activity at physio- 
logical pH values; e.g., EC-2 has maximal activity in vitro at pH 7.4 whereas 
EC-1 has no more than 77% of its optimal activity at this pH (10). 
The permanent cure of mice with disseminated leukemia by treatment ini- 
tiated 7 days after inoculation is unique, as it is the only instance of its kind in 
a  fully histocompatible system. The conclusion that immunological responses 
play no part in the recovery of these mice is emphasized by the finding that they 
are fully susceptible to rechallenge with minimal inocula of the same leukemia. 
The occurrence in EARAD1 of variants that do not require asparagine appears 
to be rare, or cures would not be possible. At somewhat lower levels of treat- 
ment, recurrence is the rule, but the recurrent leukemia is susceptible to re- 
treatment, indicating regrowth of the sensitive line. As x-asparaginase  is ef- 
fective in retreatment of mice with recurrent leukemia or cured mice receiving 
a second transplant it is clear that sensitization to L-asparaginase does not occur 
under these conditions, or that any antibodies which may have been formed do 
not interfere with enzyme activity. 
Of the many important questions raised by the work on L-asparaginase per- 
haps the most pressing is whether human tumors may be susceptible to this 
form of therapy. The occurrence of susceptible leukemias in mice, and of sus- 
ceptible tumors of other kinds in the rat, makes it impossible to form an opinion 
as to which class of human tumor might respond. However, the availability of 
an effective enzyme from bacterial sources will make it possible to carry out 
adequate trials with a wide variety of tumors and leukemias in species  other 
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dependence of primary  tumors obviously would be of great  value, but regardless 
of such tests final evaluation is bound to depend upon tests in vivo. 
SUMMARY 
A survey of 109 recently derived leukemias of the mouse revealed that sensi- 
tivity to suppression by guinea pig serum is a common property of transplanted 
leukemias of certain classes. The sensitive leukemias included five that arose 
spontaneously in mice of strains with a low incidence of leukemia and 21 that 
were induced by X-radiation. 
Two GPS-sensitive leukemias were not more sensitive than a  GPS-resistant 
leukemia to a range of standard chemotherapeutic agents. 
The effectiveness of L-asparaginase EC-2 from Escherich~ coli in suppression 
of the GPS-sensitive leukemia EARAD1 depends upon the conditions of assay. 
Whereas it is not inhibitory when administered as a single dose at the time of 
inoculation of the leukemia it is considerably more effective than GPS when used 
in the treatment of established leukemia. 
Permanent cures of 7-day generalized transplants of EARAD1 can be effected 
by the administration of 2000 or more units of EC-2. Immunological factors 
apparently do not contribute to cure as treated survivors are fully susceptible 
to rechallenge with minimal numbers of cells from the same leukemia. Reinocu- 
lated survivors with progressively growing transplants have been successfully 
retreated with EC-2. 
The blood clearance of EC-2 L-asparaginase injected into mice is much more 
rapid than that of GPS L-asparaginase. After intraperitoneal inoculation of the 
EC-1 L-asparaginase, which does not have leukemia-inhibitory activity, only 
very low levels of enzyme activity could be detected in the serum. 
The effectiveness of EC-2 from E. coli and its availability from a virtually 
limitless source wilt make it possible to extend the study of inhibition of leu- 
kemias and other tumors by L-asparaginase to species other than small rodents. 
We express our appreciation to Dr. C. Chester Stock for encouragement and support. 
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